These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9585355)

  • 1. Modification of levodopa responses by deprenyl (selegiline): an electrophysiological and behavioral study in the rat relevant to Parkinson's disease.
    Mercuri NB; Scarponi M; Federici M; Bonci A; Siniscalchi A; Bernardi G
    Ann Neurol; 1998 May; 43(5):613-7. PubMed ID: 9585355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons.
    Engberg G; Elebring T; Nissbrandt H
    J Pharmacol Exp Ther; 1991 Nov; 259(2):841-7. PubMed ID: 1658311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
    Greenamyre JT; Eller RV; Zhang Z; Ovadia A; Kurlan R; Gash DM
    Ann Neurol; 1994 Jun; 35(6):655-61. PubMed ID: 8210221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic treatment with levodopa and/or selegiline does not affect behavioral recovery induced by fetal ventral mesencephalic grafts in unilaterally 6-hydroxydopamine-lesioned rats.
    Adams CE; Hoffman AF; Hudson JL; Hoffer BJ; Boyson SJ
    Exp Neurol; 1994 Dec; 130(2):261-8. PubMed ID: 7867755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases.
    Knoll J
    J Neural Transm Suppl; 1993; 40():69-91. PubMed ID: 8294902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.
    Ann Neurol; 1996 Jan; 39(1):37-45. PubMed ID: 8572664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
    Srinivasan J; Schmidt WJ
    Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease.
    Mandel RJ
    Exp Neurol; 2000 Jan; 161(1):212-9. PubMed ID: 10683287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticonvulsant and antiepileptogenic effect of L-deprenyl (selegiline) in the kindling model of epilepsy.
    Löscher W; Hönack D
    J Pharmacol Exp Ther; 1995 Jul; 274(1):307-14. PubMed ID: 7616414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes.
    Knoll J
    Biomed Pharmacother; 1995; 49(4):187-95. PubMed ID: 7669938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deprenyl and levodopa and Parkinson's disease progression.
    Fowler JS; Fazzini E; Volkow ND
    Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
    [No Abstract]   [Full Text] [Related]  

  • 14. The frissonnant mutant mouse, a model of dopamino-sensitive, inherited motor syndrome.
    Callizot N; Guénet JL; Baillet C; Warter JM; Poindron P
    Neurobiol Dis; 2001 Jun; 8(3):447-58. PubMed ID: 11442353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
    Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic delivery of catecholamines in the striatum attenuate parkinsonian symptoms and widen the therapeutic window of oral sinemet in rats.
    Lindner MD; Plone MA; Mullins TD; Winn SR; Chandonait SE; Stott JA; Blaney TJ; Sherman SS; Emerich DF
    Exp Neurol; 1997 May; 145(1):130-40. PubMed ID: 9184116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiparkinsonian therapies and brain mitochondrial complex I activity.
    Przedborski S; Jackson-Lewis V; Fahn S
    Mov Disord; 1995 May; 10(3):312-7. PubMed ID: 7651449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (-)Deprenyl (Selegiline): past, present and future.
    Knoll J
    Neurobiology (Bp); 2000; 8(2):179-99. PubMed ID: 11061214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacology of (-)deprenyl.
    Knoll J
    J Neural Transm Suppl; 1986; 22():75-89. PubMed ID: 3097262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.